Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Bladder Cancer: Update Bulletin #1 [November 2018]

Product Code:
Publication Date:
November 2018

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the bladder cancer (BC) market. Within this update, KOLs provided their views on the following key events: Janssen announcing that it had submitted a New Drug Application to the US Food and Drug Administration seeking approval of erdafitinib for the treatment of locally advanced or metastatic urothelial bladder cancer (UBC); Sesen Bio’s presentation of three-month data from the ongoing Phase III VISTA study at the Global Congress on Bladder Cancer 2018 in Madrid; and Bavarian Nordic announcing that the first patient has been dosed in the Phase II study evaluating the combination of CV301 with atezolizumab (Tecentriq) for locally advanced or metastatic UBC.

Business Questions:

• How do KOLs view the potential of Janssen’s erdafitinib in locally advanced or metastatic urothelial bladder cancer?
• Do KOLs expect the Phase III THOR study to deliver positive data for Janssen?
• How do experts view the market potential of FGF/FGFR inhibitors and can erdafitinib differentiate itself from competitors?
• How is Sesen Bio’s Vicinium perceived by KOLs and what data do they want to see from the Phase III VISTA study?
• Do KOLs have any safety concerns for Vicinium?
• If approved, how and when do KOLs expect Vicinium to be used as a treatment for BC?
• How do experts view Bavarian Nordic’s dual immunotherapy combination (CV301 + atezolizumab) for BC?
• Do KOLs have any safety concerns with Bavarian Nordic’s CV301 + atezolizumab combination?
• How do KOLs rate the chances of CV301 + atezolizumab reaching the BC market?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved